News

The company plans to discontinue the HCV candidate development, after the completion of the one remaining clinical study that is expected in July this year. Regulus has decided to terminate

The removal was sought after concerns that the risks associated with consuming the drug outweighed its benefits, stated the FDA. In fact, it marks the first time that the

The SAPHIR study is the first clinical trial to investigate the Glutaminylcyclase (QC) inhibitor PQ912 in patients with early AD over a treatment period of 12 weeks. The

In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statistically significant reductions in A1C, a measure of average blood glucose over a

J&J signed an agreement in January this year to acquire Actelion, which develops and commercializes new drugs for diseases with significant unmet medical need. With the EC approval, the

Panobinostat will be developed by Midatech for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) as a continuation of its existing MTX110 program, and potentially for Glioblastoma (GBM).

The transaction will be funded by the Buyer Consortium through a combination of equity financing to be provided by the Buyer Consortium and debt financing, and is not

A company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group will acquire the business from Valeant. iNova is engaged in the

The investigational oral agent upadacitinib was evaluated in a phase 3 clinical trial, dubbed SELECT-NEXT, in patients with moderate to severe RA who did not respond adequately to treatment with